3-substituted indole glycal compound as well as preparation method and application thereof
By using tri-O-acetyl-D-gluenose, indole derivatives and iron catalysts in the synthesis of indole glucosides, the problems of harsh conditions and poor selectivity in the prior art are solved, and 3-substitution is achieved Highly effective synthesis and anti-inflammatory effects of indolene sugar compounds.
Patent Information
- Application Number
- CN202411185663.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-27
AI Technical Summary
The existing indole glycoside synthesis methods have harsh conditions, low yields and poor selectivity, and cannot quickly build a diversity-oriented compound library, which limits its application in drug development.
Tri-O-acetyl-D-gluene sugar, indole derivatives and iron catalysts were used to react in solvents, and the reaction conditions were controlled by pH adjustment to achieve high regioselective synthesis of 3-substituted indole sugar compounds.
It has achieved efficient synthesis with simple operation, single chirality of the product and no protection of inert gas. For the first time, the indolene sugar is synthesized with metal iron, and the product has good anti-inflammatory effects.
Smart Images

Figure CN119060029A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of chemical synthesis, and in particular to a 3-substituted indole ene sugar compound, a preparation method and application thereof. Background Art
[0002] Indole is a very important raw material in organic synthesis. Indole is also widely present in various active natural products and drug molecules. Indole glycoside compounds have various biological activities, including anti-inflammatory activity, and can be developed as potential drug precursors. The conventional synthesis method of indole carbon glycosides uses halogenated sugars or olefin sugars as raw materials to form different indole glycosides under catalysts such as metals or thioureas. The conditions are harsh, the yield is low, the selectivity is poor, the functional group tolerance is low, and it is impossible to quickly construct a compound library with diversity orientation, which limits the construction of its compound library.
[0003] Chinese patent CN116947833A "A 3-indole-deoxycarbon glycoside and its preparation method" discloses 3-indole-deoxycarbon glycoside and its preparation method, using easily synthesized olefin sugar donors and indole derivatives as raw materials, and catalyzing the indole C-3 glycosylation reaction with a cheap metal catalyst to construct 3-indole-deoxycarbon glycoside. However, the above reaction needs to be carried out under nitrogen protection, and the reaction conditions are harsh.
[0004] Therefore, it is particularly important to design a 3-substituted indole ene sugar compound and a preparation method with strong regioselectivity. Summary of the invention
[0005] The purpose of the present invention is to provide a method for preparing a 3-substituted indole sugar compound. The method has strong regioselectivity, simple operation and single chirality of the product. The present invention also provides a 3-substituted indole sugar compound, which has a good anti-inflammatory effect.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] A 3-substituted indole ene sugar compound, the structural formula of the compound is shown in 1:
[0008]
[0009] Where R 1 including hydrogen, pyrimidinyl or an acyl group of formula 2;
[0010]
[0011] Where R 3 Including amino, alkyl substituted amino, C1-5 alkyl; R 2 Including hydrogen, C1-C3 alkoxy or C1-C3 aldehyde.
[0012] Further R 1 Including pyrimidinyl, amide, and pivaloyl.
[0013] The compound represented by Formula 1 includes the following structure:
[0014]
[0015] A method for synthesizing a 3-substituted indolene sugar compound comprises the following steps: mixing tri-O-acetyl-D-glucal, an indole derivative and an iron-containing catalyst in a solvent to obtain the 3-substituted indolene sugar compound.
[0016] Furthermore, the iron-containing catalyst includes one or more of ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferric perchlorate monohydrate, ferric chloride, and ferric bromide.
[0017] Furthermore, the solvent includes: one or both of ethylene dichloride and toluene.
[0018] Furthermore, during the reaction, the pH is controlled to be 6-9 by a pH regulator.
[0019] Furthermore, the pH adjuster includes one or more of potassium acetate, potassium phosphate, sodium carbonate and sodium acetate.
[0020] Furthermore, the fourth position of the indole derivative is connected with a C1-C3 alkoxy group or a C1-C3 aldehyde group.
[0021] The invention also discloses application of a 3-substituted indole ene sugar compound in the preparation of anti-inflammatory drugs.
[0022] The reaction mechanism route of the present invention is:
[0023]
[0024] In the above route, R 1 Including hydrogen, pyrimidinyl, amide, acylalkyl; R 2 Including hydrogen, C1-C3 alkoxy or C1-C3 aldehyde.
[0025] Beneficial effects:
[0026] The preparation method of the invention has strong regioselectivity, and only 3-substituted indole olefin sugar is obtained by reaction; no inert gas protection is required, and the operation is simple; the indole olefin sugar is synthesized by metallic iron catalysis for the first time; when there is a substituent at the 4-position of indole, only a stereospecific α-configuration 3-substituted olefin sugar product is obtained.
[0027] The 3-substituted indolene sugar compound disclosed by the invention has good anti-inflammatory effect.
[0028] Other features and advantages of the present invention will be described in the following description, and partly become apparent from the description, or understood by practicing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures pointed out in the description, claims and drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0030] Figure 1 is the H NMR spectrum of compound 4aa obtained in Example 1 in the specific embodiment;
[0031] Figure 2 This is the H NMR spectrum of compound 4ag obtained in Example 2 in the specific implementation manner;
[0032] Figure 3 This is the H NMR spectrum of compound 4ak obtained in Example 3 in the specific implementation manner;
[0033] Figure 4 This is the H NMR spectrum of compound 4a1 obtained in Example 4 in the specific implementation manner;
[0034] Figure 5 The crystal structure diagram of compound 4aa obtained in Example 1 in the specific embodiment;
[0035] Figure 6 is the survival rate of inflammatory cells by samples 4a1 (sample 1) and 4aa (sample 2) in a specific embodiment;
[0036] Figure 7 It is a comparison chart of the effects of samples 4a1 (sample 1) and 4aa (sample 2) on inflammatory cell proliferation before and after 24 hours of administration in a specific embodiment;
[0037] Figure 8 In the specific implementation manner, the absorbance of samples 4a1 (sample 1) and 4aa (sample 2) was detected by CCK8 and the statistical difference diagram was shown. Figure 8 (a) is the absorbance graph, Figure 8 (b) is the statistical difference diagram. DETAILED DESCRIPTION
[0038] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0039] Example 1
[0040] The present invention adopts a model reaction: the substrate N-pyrimidine indole derivative 3a (195.23, 0.1mmol, 19.5mg), the substrate tri-O-acetyl-D-glucal 2a (272.25, 0.2mmol, 54.5mg), the catalyst ferric bromide (295.56, 0.01mmol, 3.0mg) and the base sodium acetate (82.03, 0.2mmol, 16.4mg) are placed in a Schlenk tube, 1.0mL of solvent toluene is added, and the reaction is stirred magnetically at 120°C for 24h to obtain the target compound 4aa. The reaction route is shown below. The final product is tested, and the nuclear magnetic hydrogen spectrum of 4aa is shown in Figure 1 The crystal structure of 4aa is shown in Figure 5 .
[0041]
[0042] Example 2
[0043] The substrate NN dimethylaminoformyl indole derivative 3b (188.23, 0.1mmol, 19mg), substrate tri-O-acetyl-D-glucal 2a (272.25, 0.2mmol, 54.5mg), catalyst ferric bromide (295.56, 0.01mmol, 3.0mg) and base sodium acetate (82.03, 0.2mmol, 16.4mg) were placed in a Schlenk tube, 1.0mL solvent toluene was added, and the reaction was stirred magnetically at 120°C for 24h to obtain the target compound 4ag. The final product was tested, and the nuclear magnetic hydrogen spectrum of 4ag is shown in Figure 2 .
[0044]
[0045] Example 3
[0046] The substrate N-pivaloyl-4-methoxyindole derivative 3c (231.30, 0.1mmol, 23.2mg), the substrate tri-O-acetyl-D-glucal 2a (272.25, 0.2mmol, 54.5mg), the catalyst ferric bromide (295.56, 0.01mmol, 3.0mg) and the base sodium acetate (82.03, 0.2mmol, 16.4mg) were placed in a Schlenk tube, 1.0mL of solvent toluene was added, and the reaction was stirred magnetically at 120°C for 24h to obtain the target compound 4ak. The final product was tested, and the nuclear magnetic hydrogen spectrum of 4ak is shown in Figure 3 ,Depend on Figure 3 It can be seen that 4ak has only α configuration.
[0047]
[0048] Example 4
[0049] The substrate N-pivaloyl-4-aldehyde indole derivative 3d (229.28, 0.1mmol, 23mg), the substrate tri-O-acetyl-D-glucal 2a (272.25, 0.2mmol, 54.5mg), the catalyst ferric bromide (295.56, 0.01mmol, 3.0mg) and the base sodium acetate (82.03, 0.2mmol, 16.4mg) were placed in a Schlenk tube, 1.0mL of solvent toluene was added, and the reaction was stirred magnetically at 120°C for 24h to obtain the target compound 4al. The final product was tested, and the nuclear magnetic hydrogen spectrum of 4al is shown in Figure 4 ,Depend on Figure 4 It can be seen that 4al has only α configuration.
[0050]
[0051] The solvent optimization of compound 4aa is shown in Table 1 below
[0052] Table 1 Yield of compound 4aa Synthesis solvent optimization list
[0053] No. 2a 3a Catalysis Base Solvent Yield note 1 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc DCE 10% 24h,120℃ 2 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc Dioxane nd 24h,120℃ 3 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc <![CDATA[CH3COCH3]]> trace 24h,120℃ 4 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc <![CDATA[PhCH3]]> 32% 24h,120℃ 5 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc DMF nd 24h,120℃ 6 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc CH3CN trace 24h,120℃ 7 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc T nd 24h,120℃ 8 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc MTBE Trace 24h,120℃ 9 0.2mmol 0.1mmol <![CDATA[FeCl2 4H2O]]> N OAc DMSO nd 24h,120℃
[0054] The catalyst optimization of compound 4aa is shown in Table 2 below
[0055] Table 2 Yield of Compound 4aa Synthesis Catalyst Optimization List
[0056]
[0057]
[0058] The yield and synthesis temperature optimization of compound 4aa are shown in Table 3 below.
[0059] Table 3 Synthesis temperature optimization list of compound 4aa
[0060] No. 2a 3a Catalysis Base Solvent Yield Air 1 0.2mmol 0.1mmol <![CDATA[FeBr3]]> N OAc <![CDATA[PhCH3]]> 78% 16h,120℃ 2 0.2mmol 0.1mmol <![CDATA[FeBr3]]> N OAc <![CDATA[PhCH3]]> 55% 16h,100℃ 3 0.2mmol 0.1mmol <![CDATA[FeBr3]]> N OAc <![CDATA[PhCH3]]> 30% 16h,60℃
[0061] The optimized base of compound 4aa is shown in Table 4 below
[0062] Table 4 Yield of compound 4aa Synthetic base type optimization list
[0063] No. 2a 3a Catalysis Base Solvent Yield Air 1 0.2mmol 0.1mmol <![CDATA[FeBr3]]> KK <![CDATA[PhCH3]]> 22% 12h,120℃ 2 0.2mmol 0.1mmol <![CDATA[FeBr3]]> DMAP <![CDATA[PhCH3]]> nd 12h,120℃ 3 0.2mmol 0.1mmol <![CDATA[FeBr3]]> <![CDATA[K3PO4]]> <![CDATA[PhCH3]]> 42% 12h,120℃ 4 0.2mmol 0.1mmol <![CDATA[FeBr3]]> <![CDATA[Na2CO3]]> <![CDATA[PhCH3]]> 57% 12h,120℃ 5 0.2mmol 0.1mmol <![CDATA[FeBr3]]> DBU <![CDATA[PhCH3]]> nd 12h,120℃ 6 0.2mmol 0.1mmol <![CDATA[FeBr3]]> <![CDATA[N(Et)3]]> <![CDATA[PhCH3]]> nd 12h,120℃ 7 0.2mmol 0.1mmol <![CDATA[FeBr3]]> N OAc <![CDATA[PhCH3]]> 77% 12h,120℃ 8 0.2mmol 0.1mmol <![CDATA[FeBr3]]> N OAc <![CDATA[PhCH3]]> 86% 24h,120℃
[0064] As can be seen from Tables 1 to 4, the solvent in the present invention can be ethylene dichloride or toluene, preferably toluene; the iron-containing catalyst can be: ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferric perchlorate monohydrate, ferric chloride, ferric bromide, preferably ferric chloride; the pH adjuster includes potassium acetate, potassium phosphate, sodium carbonate, sodium acetate, preferably sodium acetate.
[0065] Detection of anti-inflammatory activity of 4aa and 4al
[0066] Add 1 mL of DMSO to 5 mg of 4al (sample 1) and 4aa (sample 2) in a spinner flask, shake and ultrasonically dissolve to obtain a mother solution. Take an appropriate amount of the mother solution and add complete culture medium to make the volume to 4 mL. Vortex thoroughly to obtain a 10 μg / mL sample solution, which is passed through a membrane for later use.
[0067] MH7A cells were digested with trypsin at 37°C for 1 minute, and then complete medium was added to terminate the digestion. The cells were pipetted into a centrifuge tube and centrifuged at 1000r×5min. The precipitate was added with 4mL complete medium to resuspend the cells. After mixing, 10μL was spotted on a cell counting plate. The cell count was calculated according to the formula and the cell mother solution was diluted to obtain 1×10 cells per mL of complete medium. 6 , take the diluent and add 100uL of cell culture medium to each well of the inner layer of the 96-well cell culture plate, and then add 200μL of PBS buffer to each well of the outermost layer to reduce water evaporation. After completing the above steps, cover the culture plate cover next to the alcohol lamp and heat the edge of the culture plate with the alcohol lamp to sterilize, spray 75% alcohol for sterilization, and then place it in a 5% CO2 incubator for 24 hours. After 24 hours, the residual culture medium was aspirated and rinsed with 100μL PBS buffer and the buffer and floating dead cells were aspirated. 100μL of drug-containing complete culture medium was added to the drug-treated group, and the same amount of complete culture medium was added to the control group. After 24 hours, the culture medium was aspirated, and 100μL of drug-containing complete culture medium containing 10% CCK8 was added to each group according to classification. After incubation for 2 hours with tin foil to avoid light, the absorbance was detected at 450nm by an enzyme label detector. The cell survival rate was calculated according to the formula.
[0068] Cell survival rate = [(AS-AB) / (AC-AB)] × 100%;
[0069] AS: absorbance of the experimental wells (culture medium containing cells, CCK8, and drugs to be tested);
[0070] AC: absorbance of control wells (culture medium containing cells, CCK8, and no drug to be tested);
[0071] AB: absorbance of blank wells (medium without cells, CCK8).
[0072] Experimental Results
[0073] like Figure 6 As shown in the figure, Normal is a control group containing CCK8 and an equal amount of cells, and its cell survival rate is the default value of 100%; due to the color error between the reagent and the complete culture medium, a blank group (containing an equal amount of complete culture medium and an equal amount of CCK8) was used to eliminate this error; Control is a control group containing TNF-α (15ng / mL) for complete culture, which is used to promote the growth of inflammatory cells. Its inflammatory cell survival rate is 112.34%, indicating that the model is successful. After inflammatory cell MH7A was co-cultured with 10μg / mL sample for 24 hours, the cell survival rates were detected by CCK8 reagent and were 89.46% and 94.79%, respectively. Figure 7 and Figure 8 The results showed that both 4al and 4aa had good anti-inflammatory effects.
[0074] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent substitutions for some of the technical features therein; and these modifications or substitutions do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A 3-substituted indole ene sugar compound, characterized in that: The structure of the compound is shown in Formula 1: Where R 1 Including hydrogen, pyrimidinyl or acyl group shown in formula 2, R 2 including hydrogen, C1-C3 alkoxy or C1-C3 aldehyde; Where R 3 Including amino, alkyl substituted amino, C1-5 alkyl.
2. The compound according to claim 1, characterized in that R 1 It is pivaloyl.
3. The compound according to claim 1, characterized in that The compound represented by Formula 1 includes the following structure:
4. A method for synthesizing the 3-substituted indolene sugar compound according to any one of claims 1 to 3, comprising the following steps: The 3-substituted indole glycoside compound is obtained by mixing tri-O-acetyl-D-glucal, an indole derivative and an iron-containing catalyst in a solvent.
5. The synthesis method according to claim 4, characterized in that The iron-containing catalyst includes one or more of ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferric perchlorate monohydrate, ferric chloride and ferric bromide.
6. The synthesis method according to claim 4, characterized in that The solvent includes: one or two of ethylene dichloride and toluene.
7. The synthesis method according to claim 4, characterized in that During the reaction, the pH is controlled to 6-9 by a pH adjuster.
8. The synthesis method according to claim 7, characterized in that The pH adjuster includes one or more of potassium acetate, potassium phosphate, sodium carbonate and sodium acetate.
9. The synthesis method according to claim 4, characterized in that The fourth position of the indole derivative is connected with a C1-C3 alkoxy group or a C1-C13 aldehyde group.
10. Use of the 3-substituted indole ene sugar compound according to claims 1 to 3 in the preparation of anti-inflammatory drugs.
Citation Information
Patent Citations
Tetrahydropyrimido[1,2-a]indole derivative, synthesis method and applications thereof
CN110357892A
2-nitro-2-ene indole sugar C-glycoside compound as well as synthesis method and application thereof
CN116789651A
3-indole-deoxy carbon glycoside and preparation method thereof
CN116947833A
3-indole or pyrrolyl-2-nitroalkene carbohydrate compound as well as preparation method and application thereof
CN118027007A
